Tempus AI, Inc. (TEM)
NASDAQ: TEM · Real-Time Price · USD
99.15
-4.10 (-3.97%)
Oct 9, 2025, 3:51 PM EDT - Market open
Tempus AI Revenue
Tempus AI had revenue of $314.64M in the quarter ending June 30, 2025, with 89.57% growth. This brings the company's revenue in the last twelve months to $951.98M, up 59.84% year-over-year. In the year 2024, Tempus AI had annual revenue of $693.40M with 30.38% growth.
Revenue (ttm)
$951.98M
Revenue Growth
+59.84%
P/S Ratio
18.37
Revenue / Employee
$396,659
Employees
2,400
Market Cap
17.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 693.40M | 161.58M | 30.38% |
| Dec 31, 2023 | 531.82M | 211.15M | 65.85% |
| Dec 31, 2022 | 320.67M | 62.82M | 24.36% |
| Dec 31, 2021 | 257.85M | 69.85M | 37.15% |
| Dec 31, 2020 | 188.00M | 125.95M | 202.95% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
TEM News
- 7 hours ago - Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy - Business Wire
- 7 hours ago - Tempus AI's $100 Breakout — Billionaire Cliff Asness Reaps 60% Windfall - Benzinga
- 8 days ago - Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density - Business Wire
- 17 days ago - Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device - Business Wire
- 24 days ago - Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease - PRNewsWire
- 27 days ago - Tempus AI stock is cheap as Murrey Math Lines points to more gains - Invezz
- 27 days ago - Tempus AI: Is TEM Stock A 10x Growth Story? - Forbes
- 4 weeks ago - Tempus AI Gains FDA Clearance For Updated Pixel To Boost Accuracy And Efficiency In Cardiac Imaging - Benzinga